Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fourth of one redeemable warrant false 0001820931 0001820931...
Alvotech et Oaktree Acquisition Corp. II ont mis en place des facilités de financement afin de renforcer la position des fonds propres de la...
Alvotech und Oaktree Acquisition Corp. II richten Finanzierungsfazilitäten ein, um die Kapitalposition des Unternehmens zu stärken und Mittel für...
Alvotech e Oaktree Acquisition Corp. II hanno creato strumenti finanziari volti a migliorare la posizione finanziaria della società e a...
Alvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company’s capital position and to replace any redeemed...
Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933...
false 0001820931 0001820931 2022-04-18 2022-04-18 0001820931 us-gaap:CapitalUnitsMember 2022-04-18 2022-04-18 0001820931...
発売後、HUKYNDRA®は欧州市場における2種類のクエン酸フリー高濃度アダリムマブバイオシミラーの1つに アルヴォテック製AVT02(アダリムマブ)の欧州および...
Dès son lancement, HUKYNDRA® sera l'un des deux biosimilaires de l'adalimumab haute concentration sans citrate sur le marché européen L'ensemble...
Mit seiner Einführung wird HUKYNDRA® zu einem von zwei zitratfreien, hochkonzentrierten Adalimumab-Biosimilars auf dem europäischen Markt Alle...
false 0001820931 0001820931 2022-04-06 2022-04-06 0001820931 us-gaap:CapitalUnitsMember 2022-04-06 2022-04-06 0001820931...
Upon launch, HUKYNDRA® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market All...
Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed...
アルヴォテックはAVT02(アダリムマブ)が規制当局の承認を経て2023年7月1日に米国で上市されると予想 アッヴィとアルヴォテックの米国で進行中の紛争は、2...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.